US Patent Issued to LUNELLA BIOTECH on Oct. 20 for "Mitoriboscins: mitochondrial-based therapeutics targeting cancer cells, bacteria, and pathogenic yeast" (British Inventors)

ALEXANDRIA, Va., Oct. 21 -- United States Patent no. 12,766,116, issued on Oct. 20, was assigned to LUNELLA BIOTECH INC. (Ontario, Canada).

"Mitoriboscins: mitochondrial-based therapeutics targeting cancer cells, bacteria, and pathogenic yeast" was invented by Michael P. Lisanti (Great Manchester, Great Britain) and Federica Sotgia (Greater Manchester, Great Britain).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present disclosure relates to inhibitors of mitochondrial function. Methods of screening compounds for mitochondrial inhibition are disclosed. Also described are methods of using mitochondrial inhibitors called mitoriboscins-mitochondrial-based therapeutic compounds having anti-cancer and antibio...